MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

NASDAQ:INKT

Overview | Financials
Company Name MiNK Therapeutics, Inc.
Symbol INKT
Currency USD
Price 0.528
Market Cap 20,878,432
Dividend Yield 0%
52-week-range 0.463 - 1.9
Industry Biotechnology
Sector Healthcare
CEO Dr. Jennifer S. Buell Ph.D.
Website https://minktherapeutics.com

An error occurred while fetching data.

About MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases,

Related Stocks

ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V.

PRQR

2.68 USD

Corvus Pharmaceuticals, Inc. logo

Corvus Pharmaceuticals, Inc.

CRVS

5.29 USD

BeyondSpring Inc. logo

BeyondSpring Inc.

BYSI

1.661 USD

Sera Prognostics, Inc. logo

Sera Prognostics, Inc.

SERA

8.1 USD

Syros Pharmaceuticals, Inc. logo

Syros Pharmaceuticals, Inc.

SYRS

0.216 USD

Catalyst Biosciences, Inc. logo

Catalyst Biosciences, Inc.

CBIO

0.511 USD

Venus Concept Inc. logo

Venus Concept Inc.

VERO

0.355 USD

Freeline Therapeutics Holdings plc logo

Freeline Therapeutics Holdings plc

FRLN

6.49 USD

Accelerate Diagnostics, Inc. logo

Accelerate Diagnostics, Inc.

AXDX

1.11 USD

Financials

Numbers are in millions USD

Numbers are in millions USD